دورية أكاديمية
Médicaments anti-obésité : leçons des échecs pour l'avenir
| العنوان: | Médicaments anti-obésité : leçons des échecs pour l'avenir Anti-obesity drugs: Lessons for the future from failures |
|---|---|
| المؤلفون: | Scheen, André |
| المصدر: | Médecine des Maladies Métaboliques, 15 (8), 734 - 743 (2021) |
| بيانات النشر: | Elsevier Masson s.r.l., 2021. |
| سنة النشر: | 2021 |
| مصطلحات موضوعية: | Anorectic drugs, Gastrointestinal peptides, Glucagon-like peptide-1, Obesity, Pharmacotherapy, Safety, antiobesity agent, gastrointestinal hormone, glucagon like peptide 1 receptor agonist, glucagon receptor agonist, hormone receptor stimulating agent, liraglutide, semaglutide, body weight loss, chronic disease, drug safety, drug tolerance, human, hypertension, non insulin dependent diabetes mellitus, obesity, Short Survey, Human health sciences, Pharmacy, pharmacology & toxicology, Sciences de la santé humaine, Pharmacie, pharmacologie & toxicologie |
| الوصف: | Both physicians and patients dream of an efficacious and safe pharmacological approach to treat obesity. Unfortunately, most anti-obesity drugs prescribed since the fifties have been associated with an unfavourable risk profile that led to numerous withdrawals during the last 25 years. Medications from pharmaco-chemistry that mainly target brain amines to reduce appetite have been abandoned because of potential cardiovascular and neuropsychiatric toxicities. More recently, biological medications emerged, in particular the glucagon-like peptide-1 (GLP-1) receptor agonist alone, such as those already on the market (liraglutide, semaglutide) or as co-agonists, combined with agonists of receptors of glucose-dependent insulinotropic polypeptide (GIP) and/or glucagon, currently in development. Whatever the drug considered, it must meet three main criteria: to support but not to replace life-style measures, to allow sufficient weight loss and to maintain this beneficial weight loss over the long term, and to be able to be administered as a safe and sustainable therapy, if obesity is considered to be a chronic disease. Because of the complexity of the pathophysiology of obesity, various combined therapies with complementary mechanisms of action would most probably be necessary to obtain a sufficient efficacy, as in type 2 diabetes and arterial hypertension. However, their tolerance and safety profile will still have to be acceptable! © 2021 Elsevier Masson SAS |
| نوع الوثيقة: | journal article http://purl.org/coar/resource_type/c_6501Test article peer reviewed |
| اللغة: | English |
| العلاقة: | urn:issn:1957-2557; urn:issn:2214-8477 |
| DOI: | 10.1016/j.mmm.2021.10.012 |
| الوصول الحر: | https://orbi.uliege.be/handle/2268/300339Test |
| حقوق: | open access http://purl.org/coar/access_right/c_abf2Test info:eu-repo/semantics/openAccess |
| رقم الانضمام: | edsorb.300339 |
| قاعدة البيانات: | ORBi |
| DOI: | 10.1016/j.mmm.2021.10.012 |
|---|